[1]袁静,郭艺芳.利尿剂在降压治疗中的应用[J].心血管病学进展,2015,(6):668-672.[doi:10.3969/j.issn.1004-3934.2015.06.004]
　YUAN Jing,GUO Yifang.Application of Diuretics in Antihypertensive Treatment[J].Advances in Cardiovascular Diseases,2015,(6):668-672.[doi:10.3969/j.issn.1004-3934.2015.06.004]
点击复制

利尿剂在降压治疗中的应用()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2015年6期
页码:
668-672
栏目:
主题综述
出版日期:
2016-06-20

文章信息/Info

Title:
Application of Diuretics in Antihypertensive Treatment
作者:
袁静; 郭艺芳
河北省人民医院,河北 石家庄 050000
Author(s):
YUAN Jing; GUO Yifang
Hebei Provincial People's Hospital, Shijiazhuang 050000,Hebei,China
关键词:
利尿剂;  降压治疗;  高血压
Keywords:
diuretics;  antihypertensive treatment;  hypertension
分类号:
R544.1; R983+.1
DOI:
10.3969/j.issn.1004-3934.2015.06.004
文献标志码:
A
摘要:
利尿剂应用于降压治疗已逾半个世纪。多项临床研究证实,此类药物降压效果好,价格低廉,且能降低心、脑血管事件的发生率和总死亡率。因此,国内外相关权威指南均肯定了利尿剂在降压领域的地位。现主要从利尿剂的分类、利尿剂的降压机制、利尿剂常见的不良反应及处理等方面对利尿剂进行总结。
Abstract:
Diuretics has been applied to the treatment of hypertension for more than half a century. A number of clinical studies have confirmed that diuretics is a very effective antihypertensive drug, and it can reduce the incidence of cardiovascular and cerebrovascular events and total mortality. This article mainly summarized the classification and antihypertensive mechanism of diuretics, and discussed its common adverse reactions and how to deal with them.

参考文献/References:

[1] Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents:a network meta-analysis[J]. JAMA, 2003,289(19):2534-2544.
[2] O'Riordan M.Half-Dose Combo of Common Diuretics a “Win-Win” for Hypertension: PATHWAY-3[EB/OL]. http://www.medscape.com/viewarticle/850422.
[3] James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee(JNC 8)[J]. JAMA, 2014,311(5):507-520.
[4] Go AS, Bauman MA,Coleman King SM,et al.An effective approach to high blood pressure control: a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention [J].Hypertension,2014,63(4):878-885.
[5] Weber MA,Schiffrin EL,White WB,et al.Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension[J]. J Hypertens, 2014,32(1):3-15.
[6] 中国高血压防治指南修订委员会.中国高血压防治指南2010[J].中国医学前沿杂志(电子版),2011,3(5):42-93.
[7] Mancia G,Fagard R,Narkiewicz K,et al.2013 ESH/ESC guidelines for the management of arterial hypertension[J]. Eur Heart J, 2013,34(28): 2159-2219.
[8] O'Riordan M. The principal results of the Prevention and Treatment of Hypertension With Algorithm-based Therapy(PATHWAY)-Optimal treatment of drug resistant hypertension-PATHWAY 2[EB/OL]. http://www.medscape.com/viewarticle/850271.

相似文献/References:

[1]李忠衡 李睿宁 叶桢 刘艺硕 孙丽杰.心力衰竭患者利尿剂抵抗的发病机制与治疗进展[J].心血管病学进展,2024,(8):717.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.010]
　LI Zhongheng,LI Ruining,YE Zhen,et al.Pathogenesis and Treatment of Diuretic Resistance in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2024,(6):717.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.010]

备注/Memo

备注/Memo:
作者简介:袁静(1981—),主治医师,硕士,主要从事高血压研究。Email:yuanjing_0@163.com 通信作者:郭艺芳(1965—),主任医师,博士,主要从事高血压、血脂等方面研究。Email:guoyifang@hotmail.com
更新日期/Last Update: 2016-06-20